The Pharmaceutical Benefits Advisory Committee (PBAC) has rejected the application to subsidise Mounjaro, the diabetes drug that can also be used for weight loss (similar to Ozempic).
Dr Namson Lau is available to provide expert commentary, and can be contacted at [email protected].
Dr. Namson Lau is a Conjoint Senior Lecturer, UNSW Sydney, and consultant endocrinologist at Liverpool and Royal Prince Alfred Hospitals. His PhD was in neuro-endocrine regulation of appetite and weight and he has extensive clinical and research expertise in type 2 diabetes, complex obesity and cardio-metabolic management.
